Bausch Health Companies Inc

Bausch Health announced the acquisition of DURECT Corporation for $63 million upfront, with potential milestone payments up to $350 million, to gain access to larsucosterol, an epigenetic modulator with FDA Breakthrough Therapy Designation for alcoholic hepatitis.

A comprehensive seven-year US pharmacovigilance analysis of brodalumab covering 5,449 patients and 7,845 patient-years of exposure shows no completed suicides and only one suicide attempt in year 3.

Tharimmune announced key leadership changes with Sireesh Appajosyula becoming CEO and Vincent LoPriore appointed Executive Chairman in June 2025.

Bausch Health Companies Inc. and Mylan Pharmaceuticals have reached a settlement agreement resolving their patent litigation over generic versions of irritable bowel syndrome (IBS) medications.

Komodo Health's healthcare intelligence platform enabled 31 research studies presented at the 2025 ISPOR global conference, including three studies led by Komodo researchers and 27 collaborative studies with academic institutions and Life Sciences companies.

The global topical drug delivery market is projected to grow from $226.31 billion in 2023 to $454.93 billion by 2031, representing a CAGR of 9.1%, driven by increasing demand for non-invasive treatment options.

Amneal Pharmaceuticals has received FDA approval for memantine/donepezil extended-release capsules, indicated for moderate to severe dementia of the Alzheimer's type.

The FDA approved mirikizumab (Omvoh) for Crohn's disease, marking its second approval in IBD after ulcerative colitis, based on positive Phase 3 trial results.

• Several companies are actively developing novel therapies for hepatic encephalopathy (HE), a neuropsychiatric condition resulting from advanced liver dysfunction. • Key players like Salix Pharmaceuticals and Vedanta Biosciences are advancing treatments such as Xifaxan and VE-303, showing promise in clinical trials. • Emerging therapies focus on innovative mechanisms like gut microbiota modulation and ammonia-lowering agents to improve patient outcomes. • Clinical trials are assessing various routes of administration and molecule types to address the unmet needs in HE treatment.

• Bausch Health's RED-C program investigates a novel rifaximin formulation (SSD-40IR) for delaying the onset of first overt hepatic encephalopathy (OHE) hospitalization in cirrhosis patients. • The Phase 3 trials are randomized, double-blind, and placebo-controlled, enrolling adults with cirrhosis and medically controlled ascites but no prior OHE history. • Topline data from the RED-C trials, which have completed enrollment across 398 sites in 17 countries, are anticipated in the first half of 2026. • Rifaximin SSD-40IR aims to enhance gastrointestinal solubility and minimize systemic exposure, potentially improving OHE prevention compared to existing treatments.